The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the inhalation cdmo industry?
The increasing prevalence of respiratory disorders is expected to propel the growth of the inhalation CDMO market going forward. Respiratory disorders are a group of medical conditions that affect the respiratory system, which includes the organs and structures involved in breathing. Inhalation CDMOs are used in the development and manufacturing of products for respiratory disorders due to their expertise in formulating and delivering drugs to the lungs, offering specialized expertise, infrastructure, and resources to pharmaceutical companies seeking to bring innovative inhalation therapies. For instance, according to the Australian Bureau of Statistics (ABS) an Australia-based Government agency, 8.5 million Australians (34%) reported having chronic respiratory conditions, including 2.8 million people (11%) with asthma and 638,000 people (2.5%) with COPD. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the inhalation CDMO market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp
What is the estimated market size of the inhalation cdmo sector by 2029, based on current forecasts?
The inhalation CDMO market size has grown strongly in recent years. It will grow from $2.08 billion in 2024 to $2.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to rising prevalence of respiratory disorders, growing demand for personalized medicine, increasing outsourcing by pharmaceutical companies, growth of the biopharmaceutical industry.
The inhalation CDMO market size is expected to see strong growth in the next few years. It will grow to $2.9 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to focus on precision medicine and targeted therapies, rapid expansion of biopharmaceutical inhalation therapies, focus on patient-centric solutions, global market expansion and emerging market opportunities, regulatory support for inhalation drug development. Major trends in the forecast period include increasing demand for digital health solutions, biologic inhalation therapies, focus on sustainable inhaler technologies, integration of artificial intelligence (AI) and machine learning, collaborations and partnerships.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13864&type=smp
#Who are the top players in the inhalation cdmo market?
Major companies operating in the inhalation CDMO market report are Pfizer Inc., Merck KGaA, Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific
#What are the major trends in the inhalation cdmo market?
Major companies operating in the inhalation CDMO industry are adopting a strategic partnership approach to provide specialized drug development and delivery. A strategic partnership is a long-term, mutually beneficial arrangement between two or more companies that work together to achieve shared goals. For instance, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, partnered with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to develop Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This partnership focuses on developing new technologies that can deliver higher doses of drugs and improve the efficiency of drug delivery to the lungs.
Which geography holds the highest inhalation cdmo market share?
North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2024. The regions covered in the inhalation CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report
How do different segments contribute to the overall expansion of the inhalation cdmo market?
The inhalation CDMO market covered in this report is segmented –
1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler
2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
3) By Technology: Manual Inhalers (SMI), Digital Inhalers
4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs
2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs
3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers
4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13864
What defines the structure and scope of the inhalation cdmo market?
An inhalation contract development and manufacturing organization (CDMO) is a specialized organization that provides comprehensive services to pharmaceutical and biotechnology firms for the development and manufacturing of inhalable drugs. These organizations offer a range of services tailored specifically to the needs of inhalation products, including formulation development, analytical testing, process optimization, scale-up, and commercial manufacturing.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
